![Keith D. Terry](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Keith D. Terry
Plus aucun poste en cours
Profil
Keith D.
Terry was the founder of OcuSub, Inc. which was founded in 2002, where he held the title of SVP-Commercial & Business Development from 2002 to 2013.
He also worked as a Managing Director at PathoGenesis Corp.
Mr. Terry has an MBA from The University of Chicago and an undergraduate degree from the University of Wisconsin.
Anciens postes connus de Keith D. Terry
Sociétés | Poste | Fin |
---|---|---|
PathoGenesis Corp
![]() PathoGenesis Corp BiotechnologyHealth Technology Part of Novartis AG, PathoGenesis Corp is a company that develops and markets innovative treatments for chronic infectious diseases. The company is based in Seattle, WA. The company was founded by Isaac Blech. PathoGenesis was acquired by Chiron Corp. on September 19, 2000 for $639.75 million. | Corporate Officer/Principal | - |
OcuSub, Inc.
![]() OcuSub, Inc. BiotechnologyHealth Technology OcuSub, Inc. engages biotechnology services. It specializes in eye disorder treatment. The company was founded by Mina Patel Sooch, Alan R. Meyer, and William H. Pitlick in 2018 and is headquartered in Farmington Hills, MI. | Fondateur | - |
Formation de Keith D. Terry
University of Wisconsin | Undergraduate Degree |
The University of Chicago | Masters Business Admin |
Expériences
Fonctions occupées
Sociétés liées
Entreprise privées | 2 |
---|---|
OcuSub, Inc.
![]() OcuSub, Inc. BiotechnologyHealth Technology OcuSub, Inc. engages biotechnology services. It specializes in eye disorder treatment. The company was founded by Mina Patel Sooch, Alan R. Meyer, and William H. Pitlick in 2018 and is headquartered in Farmington Hills, MI. | Health Technology |
PathoGenesis Corp
![]() PathoGenesis Corp BiotechnologyHealth Technology Part of Novartis AG, PathoGenesis Corp is a company that develops and markets innovative treatments for chronic infectious diseases. The company is based in Seattle, WA. The company was founded by Isaac Blech. PathoGenesis was acquired by Chiron Corp. on September 19, 2000 for $639.75 million. | Health Technology |